| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| KRYSKrystal Biotech, Inc. | 8.18B | 282.01 | 94.00 | 473.02% | 53.3% | 17.48% | 1.46% | 0.01 |
| BMRNBioMarin Pharmaceutical Inc. | 10.58B | 55.07 | 24.92 | 17.97% | 16.82% | 8.59% | 4.49% | 0.11 |
| SRPTSarepta Therapeutics, Inc. | 2.23B | 21.31 | 9.11 | 52.97% | -11.25% | -20.57% | 0.88 | |
| RAREUltragenyx Pharmaceutical Inc. | 2.27B | 23.50 | -3.74 | 29.01% | -91.95% | -35.88% | 0.15 | |
| DYNDyne Therapeutics, Inc. | 2.7B | 16.42 | -4.87 | -61.26% | 0.04 | |||
| TVTXTravere Therapeutics, Inc. | 2.54B | 28.40 | -6.96 | 60.55% | -20.32% | -120.36% | 6.80 | |
| BEAMBeam Therapeutics Inc. | 3.25B | 32.05 | -7.00 | -83.18% | -7.44% | -42.92% | 0.22 | |
| SLNOSoleno Therapeutics, Inc. | 2.25B | 41.95 | -9.58 | -79.5% | -15.85% | 0.22 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 20.61K | 41.3K | 28.88K | 133.93K | 132.64K | 55.18K | 0 |
| Revenue Growth % | - | 1% | -0.3% | 3.64% | -0.01% | -0.58% | -1% |
| Cost of Goods Sold | 0 | 0 | 0 | 7.16M | 8.24M | 0 | 0 |
| COGS % of Revenue | - | - | - | 53.49% | 62.15% | - | - |
| Gross Profit | 0 | 41.3K | 28.88K | -7.03M | -8.11M | 55.18K | 0 |
| Gross Margin % | - | 1% | 1% | -52.49% | -61.15% | 1% | - |
| Gross Profit Growth % | - | - | -0.3% | -244.42% | -0.15% | 1.01% | -1% |
| Operating Expenses | 1.05M | 2.14M | 3.51M | 6.8M | 9.67M | 22.31M | 20.35M |
| OpEx % of Revenue | 50.9% | 51.85% | 121.48% | 50.74% | 72.88% | 404.28% | - |
| Selling, General & Admin | 222.05K | 555.16K | 1.25M | 6.84M | 9.68M | 10.79M | 9.56M |
| SG&A % of Revenue | 10.77% | 13.44% | 43.25% | 51.06% | 73.01% | 195.5% | - |
| Research & Development | 826.88K | 1.59M | 2.26M | 7.35M | 8.46M | 11.52M | 10.79M |
| R&D % of Revenue | 40.12% | 38.41% | 78.22% | 54.87% | 63.78% | 208.78% | - |
| Other Operating Expenses | 0 | 0 | 0 | -7.39M | -8.48M | 0 | 0 |
| Operating Income | -1.03M | -2.1M | -3.48M | -13.83M | -17.78M | -22.25M | -20.35M |
| Operating Margin % | -49.9% | -50.85% | -120.48% | -103.24% | -134.02% | -403.28% | - |
| Operating Income Growth % | - | -1.04% | -0.66% | -2.97% | -0.29% | -0.25% | 0.09% |
| EBITDA | -1.03M | -2.1M | -3.47M | -13.81M | -17.75M | -22.17M | -20.27M |
| EBITDA Margin % | -49.86% | -50.79% | -120.14% | -103.12% | -133.82% | -401.77% | - |
| EBITDA Growth % | - | -1.04% | -0.65% | -2.98% | -0.29% | -0.25% | 0.09% |
| D&A (Non-Cash Add-back) | 741 | 2.57K | 9.59K | 15.48K | 26.63K | 83.58K | 84.07K |
| EBIT | -1.03M | -2.1M | -3.48M | -13.84M | -17.79M | -22.25M | -20.35M |
| Net Interest Income | -52.48K | -20.54K | 3.64K | 12.49K | 375.36K | 494.23K | 357.1K |
| Interest Income | 0 | 0 | 3.64K | 12.49K | 375.36K | 494.23K | 357.1K |
| Interest Expense | 52.48K | 20.54K | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -67.44K | -86.22K | -92.85K | -60.42K | 279.28K | 64.89K | 476.22K |
| Pretax Income | -1.1M | -2.19M | -3.57M | -13.89M | -17.5M | -22.19M | -19.87M |
| Pretax Margin % | -53.17% | -52.94% | -123.69% | -103.69% | -131.92% | -402.11% | - |
| Income Tax | 9.78K | 7.11K | 5.39K | 4.01K | 92.98K | 79.28K | 536.82K |
| Effective Tax Rate % | 1.01% | 1% | 1% | 1% | 1.01% | 1% | 1.03% |
| Net Income | -1.11M | -2.19M | -3.58M | -13.89M | -17.59M | -22.27M | -20.41M |
| Net Margin % | -53.64% | -53.11% | -123.88% | -103.72% | -132.62% | -403.54% | - |
| Net Income Growth % | - | -0.98% | -0.63% | -2.88% | -0.27% | -0.27% | 0.08% |
| Net Income (Continuing) | -1.11M | -2.19M | -3.58M | -13.89M | -17.59M | -22.27M | -20.41M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.19 | -0.26 | -0.30 | -1.37 | -1.48 | -1.71 | -0.89 |
| EPS Growth % | - | -0.37% | -0.15% | -3.57% | -0.08% | -0.16% | 0.48% |
| EPS (Basic) | -0.19 | -0.37 | -0.30 | -1.37 | -1.48 | -1.71 | -0.89 |
| Diluted Shares Outstanding | 5.86M | 8.37M | 11.88M | 10.17M | 11.88M | 13.01M | 22.88M |
| Basic Shares Outstanding | 5.86M | 8.37M | 11.88M | 10.17M | 11.88M | 13.01M | 22.88M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 494.64K | 398.05K | 8.99M | 37.72M | 21.09M | 17.78M | 11.6M |
| Cash & Short-Term Investments | 400.69K | 303.32K | 7.49M | 36.88M | 20.14M | 16.79M | 10.39M |
| Cash Only | 400.69K | 303.32K | 7.49M | 36.88M | 7.31M | 11.79M | 10.39M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 12.83M | 5M | 0 |
| Accounts Receivable | 0 | 44.91K | 8.55K | 195.45K | 103.88K | 242.58K | 765.76K |
| Days Sales Outstanding | - | 396.94 | 108.03 | 532.66 | 285.85 | 1.6K | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 93.94K | 0 | 1.29M | 0 | 640.31K | 0 | 369.89K |
| Total Non-Current Assets | 317K | 262.24K | 616.53K | 1.26M | 3.01M | 830.46K | 521.41K |
| Property, Plant & Equipment | 305.79K | 219.35K | 552.71K | 1.01M | 804.31K | 585.18K | 323.33K |
| Fixed Asset Turnover | 0.07x | 0.19x | 0.05x | 0.13x | 0.16x | 0.09x | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 202.61K | 213.97K | 193.38K | 134.27K |
| Long-Term Investments | 0 | 10.38K | 0 | 31.28K | 1.94M | 0 | 31.7K |
| Other Non-Current Assets | 11.21K | 32.51K | 63.82K | 53.39K | 48.32K | 51.91K | 32.11K |
| Total Assets | 811.63K | 660.29K | 9.6M | 38.99M | 24.1M | 18.61M | 12.12M |
| Asset Turnover | 0.03x | 0.06x | 0.00x | 0.00x | 0.01x | 0.00x | - |
| Asset Growth % | - | -0.19% | 13.55% | 3.06% | -0.38% | -0.23% | -0.35% |
| Total Current Liabilities | 530.79K | 879.05K | 2.11M | 2.55M | 4.13M | 4.95M | 3.91M |
| Accounts Payable | 149.33K | 154.44K | 961.52K | 560.48K | 1.63M | 1.32M | 946.26K |
| Days Payables Outstanding | - | - | - | 28.55 | 72 | - | - |
| Short-Term Debt | 0 | 102.11K | 22.63K | 103.83K | 108.14K | 118.8K | 110.18K |
| Deferred Revenue (Current) | 0 | 368.8K | 0 | 266.5K | 55.18K | 1000K | 252.21K |
| Other Current Liabilities | 159.51K | 250K | 245.86K | 380 | 364.11K | 1.38M | 18.49K |
| Current Ratio | 0.93x | 0.45x | 4.25x | 14.78x | 5.11x | 3.59x | 2.97x |
| Quick Ratio | 0.93x | 0.45x | 4.25x | 14.78x | 5.11x | 3.59x | 2.97x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 1.23M | 231.09K | 1.29M | 1.61M | 1.09M | 1.08M | 872.99K |
| Long-Term Debt | 1.01M | 0 | 715.66K | 590.47K | 495.26K | 449.05K | 328.33K |
| Capital Lease Obligations | 200.95K | 98.84K | 400.32K | 695.05K | 441.78K | 229.85K | 53.6K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 23.98K | 132.25K | 171.56K | 329.46K | 157.58K | 307.45K | 443.62K |
| Total Liabilities | 1.76M | 1.11M | 3.4M | 4.17M | 5.22M | 6.03M | 4.78M |
| Total Debt | 1.31M | 200.95K | 1.26M | 1.61M | 1.27M | 1.03M | 653.01K |
| Net Debt | 807.08K | -102.37K | -6.23M | -35.27M | -6.04M | -10.77M | -9.73M |
| Debt / Equity | - | - | 0.20x | 0.05x | 0.07x | 0.08x | 0.09x |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - |
| Interest Coverage | -19.60x | -102.24x | - | - | - | - | - |
| Total Equity | -950.91K | -449.86K | 6.2M | 34.82M | 18.88M | 12.58M | 7.34M |
| Equity Growth % | - | 0.53% | 14.79% | 4.61% | -0.46% | -0.33% | -0.42% |
| Book Value per Share | -0.16 | -0.05 | 0.52 | 3.43 | 1.59 | 0.97 | 0.32 |
| Total Shareholders' Equity | -950.91K | -449.86K | 6.2M | 34.82M | 18.88M | 12.58M | 7.34M |
| Common Stock | 225 | 225 | 354 | 1.19K | 1.19K | 1.62K | 2.71K |
| Retained Earnings | -1.26M | -3.46M | -7.03M | -20.93M | -38.52M | -60.78M | -81.19M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 3.08K | -81.16K | -152.7K | -90.64K | 35.63K | 247.24K | -247.55K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -744.51K | -1.87M | -3.24M | -12.37M | -14.69M | -18.87M | -18.87M |
| Operating CF Margin % | -36.13% | -45.24% | -112.19% | -92.33% | -110.77% | -341.9% | - |
| Operating CF Growth % | - | -1.51% | -0.73% | -2.82% | -0.19% | -0.28% | -0% |
| Net Income | -1.11M | -2.19M | -3.58M | -13.89M | -17.59M | -22.27M | -20.41M |
| Depreciation & Amortization | 741 | 2.57K | 9.59K | 15.48K | 64.17K | 83.58K | 84.07K |
| Stock-Based Compensation | 0 | 0 | 81.64K | 839.37K | 1.53M | 3.26M | 2.39M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 41.05K | 10.1K | 8.71K | 999.87K | -206.86K | -383.19K | 143.52K |
| Working Capital Changes | 319.23K | 312.26K | 237.5K | -329.78K | 1.51M | 442.23K | -1.08M |
| Change in Receivables | 0 | -8.35K | -21.65K | -63.35K | 3.63K | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 117.69K | 5.11K | 395.54K | -521.39K | 1.07M | -643.16K | 274.89K |
| Cash from Investing | -7.99K | -13.72K | -20.83K | -94.21K | -14.77M | 10.22M | 4.98M |
| Capital Expenditures | -7.99K | -13.72K | -20.83K | -94.21K | -118.95K | -15.36K | -22.49K |
| CapEx % of Revenue | 0.39% | 0.33% | 0.72% | 0.7% | 0.9% | 0.28% | - |
| Acquisitions | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 983.78K | 1.75M | 10.49M | 41.77M | -78.77K | 12.64M | 13.01M |
| Debt Issued (Net) | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - |
| Other Financing | 0 | 0 | -470.75K | -841.27K | 0 | 0 | -109.36K |
| Net Change in Cash | - | - | - | - | - | - | - |
| Free Cash Flow | -752.5K | -1.88M | -3.26M | -12.46M | -14.81M | -18.88M | -18.9M |
| FCF Margin % | -36.51% | -45.57% | -112.91% | -93.03% | -111.66% | -342.18% | - |
| FCF Growth % | - | -1.5% | -0.73% | -2.82% | -0.19% | -0.27% | -0% |
| FCF per Share | -0.13 | -0.22 | -0.27 | -1.23 | -1.25 | -1.45 | -0.83 |
| FCF Conversion (FCF/Net Income) | 0.67x | 0.85x | 0.91x | 0.89x | 0.84x | 0.85x | 0.92x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 9.44K | 4.57K | 4.47K | 2.74K | 134.96K | 86.31K |
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -124.39% | -67.73% | -65.52% | -141.57% | -204.95% |
| Return on Invested Capital (ROIC) | - | - | - | - | -215.26% | -227.8% | - |
| Gross Margin | - | 100% | 100% | -5249.31% | -6114.63% | 100% | - |
| Net Margin | -5364.36% | -5310.88% | -12387.67% | -10371.7% | -13262.02% | -40354.33% | - |
| Debt / Equity | - | - | 0.20x | 0.05x | 0.07x | 0.08x | 0.09x |
| Interest Coverage | -19.60x | -102.24x | - | - | - | - | - |
| FCF Conversion | 0.67x | 0.85x | 0.91x | 0.89x | 0.84x | 0.85x | 0.92x |
| Revenue Growth | - | 100.4% | -30.07% | 363.72% | -0.96% | -58.4% | -100% |
Gain Therapeutics, Inc. (GANX) saw revenue decline by 100.0% over the past year.
Gain Therapeutics, Inc. (GANX) reported a net loss of $19.4M for fiscal year 2024.
Gain Therapeutics, Inc. (GANX) has a return on equity (ROE) of -205.0%. Negative ROE indicates the company is unprofitable.
Gain Therapeutics, Inc. (GANX) had negative free cash flow of $17.3M in fiscal year 2024, likely due to heavy capital investments.